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Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator that regulates many processes in inflammation and cancer. S1P is a
ligand for five G-protein-coupled receptors, S1PR1 to -5, and also has important intracellular actions. Previously, we showed
that intracellular S1P is involved in tumor necrosis factor alpha (TNF)-induced NF-B activation in melanoma cell lines that
express filamin A (FLNA). Here, we show that extracellular S1P activates NF-B only in melanoma cells that lack FLNA. In these
cells, S1P, but not TNF, promotes IB kinase (IKK) and p65 phosphorylation, IB degradation, p65 nuclear translocation, and
NF-B reporter activity. NF-B activation induced by S1P was mediated via S1PR1 and S1PR2. Exogenous S1P enhanced the
phosphorylation of protein kinase C (PKC), and its downregulation reduced S1P-induced the phosphorylation of IKK and
p65. In addition, silencing of Bcl10 also inhibited S1P-induced IKK phosphorylation. Surprisingly, S1P reduced Akt activation in
melanoma cells that express FLNA, whereas in the absence of FLNA, high phosphorylation levels of Akt were maintained, en-
abling S1P-mediated NF-B signaling. In accord, inhibition of Akt suppressed S1P-mediated IKK and p65 phosphorylation and
degradation of IB. Hence, these results support a negative role of FLNA in S1P-mediated NF-B activation in melanoma cells
throughmodulation of Akt.
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid me-tabolite that regulates a myriad of physiological processes, in-
cluding cell growth, survival, migration, and differentiation. S1P
plays important roles in disorders of the immune and cardiovas-
cular systems as well as in cancer (1–3). Most of the actions of S1P
are mediated by binding to five specific S1P receptors, named
S1PR1 to -5 (4, 5). These receptors are coupled to distinct hetero-
trimeric G proteins leading to downstream activation of diverse
effector pathways, including phospholipase C (PLC), phosphati-
dylinositol 3-kinase (PI3K), and mitogen-activated protein ki-
nases (MAPKs), among others (6).
S1P produced inside cells by the activation of two sphingosine
kinases, SphK1 and SphK2 (3, 4), can be exported by either the
specific transporter Spns2 (7) or several members of the ABC
transporter family (8). S1P then acts in an autocrine or paracrine
manner by a process coined “inside-out signaling” (3, 4). In this
regard, we previously showed that the actin cross-linking protein
filamin A (FLNA) is involved in inside-out signaling of S1P by
linking SphK1 and S1PR1 at the leading edge of melanoma cells to
promote cell movement (9). In addition, FLNA also associates
with multiple noncytoskeletal proteins with diverse functions and
provides a scaffold for a wide range of cytoplasmic and nuclear
signaling proteins (10). For example, FLNA interacts with tumor
necrosis factor (TNF) receptor-associated factor 2 (TRAF2) to
promote the activation of NF-B in melanoma cells (11). Inter-
estingly, SphK1 binds both TRAF2 and FLNA, suggesting that the
production of S1P has an important role in NF-B signaling (9,
12). Indeed, we have recently shown that S1P formed intracellu-
larly by TNF-mediated activation of SphK1 binds to and is a re-
quired cofactor for the E3 ubiquitin ligase activity of TRAF2, a key
step in the NF-B pathway (13). On the other hand, S1P also
activates NF-B by binding to specific S1PRs (14–16). However,
the signaling pathways downstream of S1PRs leading to the acti-
vation of NF-B are not fully understood. Thus, in the present
work, we evaluated how extracellular S1P activates NF-B and the
role of FLNA in this mechanism.
MATERIALS AND METHODS
Reagents. S1P was obtained from Enzo Life Sciences (Farmingdale, NY),
and TNF- was obtained from Roche (Hague Road, IN). JTE013 (S1PR2
antagonist) and VPC23019 (S1PR1/3 antagonist) were obtained from
Avanti Polar Lipids (Alabaster, AL). W146 (S1PR1 antagonist),
CAY10444 (S1PR3 antagonist), and SEW2871 (S1PR1 agonist) were ob-
tained from Cayman Chemical (Ann Arbor, MI). CYM-5520 (S1PR2 ag-
onist), phorbol 13-myristate 12-acetate (PMA) (diacylglycerol [DAG]-
dependent protein kinase C [PKC] activator), Go6983 (PKC inhibitor),
and rottlerin (PKC inhibitor) were obtained from Sigma (St. Louis,
MO). Primary antibodies directed against phospho-p65 (S536), phospho-
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IB kinase/ (IKK/) (S176/180), phospho-IB (S32/36), total IB
(mouse monoclonal antibody [MAb] L35A5), phospho-Akt (S473),
phospho-PKC, phospho-STAT3 (Tyr705), and Akt were obtained from
Cell Signaling (Beverly, MA). Extracellular signal-regulated kinase 1/2
(ERK1/2) (T202/Y204) and -tubulin antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). FLNA antibody was ob-
tained from Abgent (San Diego, CA). S1PR1, S1PR2, and S1PR3 antibod-
ies were obtained from Abcam (Cambridge, MA). Appropriate horserad-
ish peroxidase (HRP)-conjugated secondary antibodies were obtained
from Jackson ImmunoResearch (West Grove, PA). Oligofectamine trans-
fection reagent was purchased from Invitrogen (Carlsbad, CA). Small
interfering RNAs (siRNAs) for SphK1, Bcl10, and PKC and control
siRNA (siControl) were obtained from Qiagen (Valencia, CA), and hu-
man FLNA siRNA was obtained from Thermo Scientific Dharmacon (La-
fayette, CO).
Cell culture. M2 and A7 melanoma cells were cultured in minimal
essential medium (MEM) (Gibco, USA) supplemented with 10% fetal
bovine serum as described previously (9). M2 and A7 are a matched pair
of cell lines: M2 cells are parental cells that do not express detectable levels
of FLNA, while A7 cells are derived from M2 cells and stably express FLNA
at near-normal levels (17). A7 cells were also cultured in the presence of
0.5 mg/ml G418. Lu1205 BRAFV600E (mutant), Sk-mel2 BRAFwt (wild-
type), WM35, and FM16 melanoma cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM). SH-SY5Y human neuroblastoma
cells were cultured in DMEM supplemented with 10% fetal bovine serum.
For experiments, cells plated into 6- or 12-well plates were cultured for 48
h at 37°C and serum starved overnight. Cells were treated with 100 nM
S1P in serum-free MEM plus 4 mg/ml bovine serum albumin (BSA) (fatty
acid free and gamma-globulin free; Sigma), 10 ng/ml TNF, or 200 nM
PMA unless indicated otherwise. Cells were preincubated for 30 min with
inhibitors or S1PR antagonists or agonists, as indicated in the figure leg-
ends.
For siRNA transfections, cells were plated into six-well plates at a
density of 80,000 cells/well and transfected with Oligofectamine and a
specific siRNA or siControl, as previously described (13). Downregula-
tion of expression was confirmed by immunoblotting and/or quantitative
PCR (QPCR).
Quantitative real-time PCR.Total RNA was isolated with TRIzol (In-
vitrogen, Carlsbad, CA) and reverse transcribed with the High Capacity
cDNA reverse transcription kit, premixed primer-probe sets, and Taq-
Man Universal PCR master mix (Applied Biosystems, USA). The
cDNAs were diluted 10-fold (for the target genes) and amplified by using
the ABI 7900HT cycler. Gene expression levels were normalized to glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) levels and are shown
as mean values  standard deviations (SD).
Western blotting. Cells were washed with ice-cold phosphate-buff-
ered saline (PBS) and scraped into lysis buffer containing 20 mM Tris-
HCl (pH 7.4), 1 mM EDTA, 150 mM NaCl, 1% Triton X-100, 1 mM
-mercaptoethanol, 1 mM Na3VO4, and a 1:500 dilution of a protease
inhibitor cocktail (Cayman, Ann Arbor, MI). Lysates were incubated on
ice for 1 h and centrifuged at 10,000 g for 10 min. Proteins (30g) were
separated by SDS-PAGE and blotted onto nitrocellulose. Membranes
were cut between high- and low-molecular-weight markers and incubated
overnight at 4°C with specific primary antibodies (1:1,000). Immunopo-
sitive bands were visualized by enhanced chemiluminescence using sec-
ondary antibodies conjugated with horseradish peroxidase (1:10,000) at
room temperature for 2 h and Super-Signal West Pico chemiluminescent
substrate (Pierce Chemical Co., Rockford, IL). Blots were stripped and
developed with antitubulin as a loading control. Optical densities of bands
associated with proteins of interest were quantified by using Image Stu-
dio Lite (Li-Cor Biosciences, Lincoln, NE) or AlphaEaseFC software
(Alpha Innotech, Miami, FL) and normalized to the optical densities of
their respective tubulin bands.
Nuclear extracts. Cells were washed with cold PBS; resuspended in
buffer containing 10 mM HEPES (pH 7.8), 10 mM KCl, 0.1 mM EDTA, 1
mM Na3VO4, 1 mM dithiothreitol (DTT), and a 1:500 dilution of pro-
tease inhibitors (Sigma); and incubated on ice for 15 min. NP-40 was
added to 0.75% (vol/vol), and cells were vortexed for 10 s. Nuclei and the
supernatant (“cytoplasm”) were separated by centrifugation at 1,000 g
for 3 min at 4°C. Nuclei were resuspended in buffer containing 20 mM
HEPES (pH 7.8), 0.4 M NaCl, 1 mM EDTA, 1 mM Na3VO4, 1 mM DTT,
and a 1:500 dilution of protease inhibitors and incubated on ice for 15
min. Nuclear extracts were cleared by centrifugation at 14,000  g for 5
min at 4°C.
NF-B reporter assay. M2 and A7 cells were transiently transfected
with pNF-B-Luc and pRSV--galactosidase. Forty-eight hours after
transfection, cells were stimulated with TNF and S1P, and luciferase and
-galactosidase activities were determined with the Dual-Light chemilu-
minescent reporter gene assay (Tropix USA). Luciferase activity was nor-
malized to -galactosidase activity as described previously (13).
Electrophoreticmobility shift assays.Electrophoretic mobility shift
assays (EMSAs) were performed with 5 g of nuclear protein and
[-32P]dCTP-end-labeled double-strand oligonucleotides containing
an NF-B consensus binding site (10 fmol; 10,000 cpm), as described
previously (13).
Apoptosis assay. Apoptosis was determined with the Cell Death De-
tection ELISAPlus kit (Roche) according to the manufacturer’s protocols.
Briefly, this assay measures mono- and oligonucleosomes in apoptotic-
cell lysates. Lysates in streptavidin-coated microplates were incubated
with antihistone/biotin and anti-DNA/peroxidase. Peroxidase activity in
the immunocomplexes was measured at 405 nm after incubation with
2,2=-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid).
Immunofluorescence. Cells grown on glass coverslips and treated as
indicated were fixed with 4% paraformaldehyde for 10 min, washed with
10 mM glycine in PBS to quench fixation, and permeabilized with 0.5%
Triton X-100 for 2 min. After incubation with anti-p65 antibody (Santa
Cruz Biotechnology) in 10 mg/ml BSA in PBS-glycine for 20 min, the
coverslips were washed and then incubated for 10 min with Alexa 488 –
anti-rabbit secondary antibody (Invitrogen) in 10 mg/ml BSA in PBS
containing 8 mg/ml Hoechst dye. Coverslips were mounted onto slides
with 10 mM n-propylgallate in 100% glycerol and visualized on a Zeiss
LSM 700 laser confocal microscope (13).
Statistical analysis. Statistical analysis was performed by using un-
paired two-tailed Student’s t test for comparison of two groups and one-
way analysis of variance (ANOVA) with Bonferroni post hoc comparison
for experiments consisting of three or more groups (Prism; GraphPad
Software, La Jolla, CA). A P value of 	0.01 was considered significant.
Experiments were repeated at least three times, with consistent results.
RESULTS
S1P activates NF-B only in melanoma cells lacking FLNA. We
have previously shown that intracellular S1P is required for TNF-
induced NF-B activation in A7 melanoma cells (13) that stably
express FLNA at near-normal levels (17). However, in agreement
with the results of our previous study (13), treatment of these cells
with 100 nM exogenous S1P, a concentration that activates signal-
ing pathways downstream of S1PRs, did not increase the phos-
phorylation of IKK, an enzyme complex containing two highly
homologous kinase subunits, IKK and IKK, that phosphorylate
IB, leading to its proteasomal degradation (Fig. 1A, left). In
contrast, as was reported previously (11), although TNF induced
robust IB degradation in A7 cells, it had no effect on M2 cells
that do not express FLNA (Fig. 1B). Similarly, TNF, but not 100
nM S1P, stimulated the phosphorylation of IKK and IB degra-
dation in other melanoma cells that express FLNA, including
weakly aggressive WM35 cells and the immortalized normal hu-
man melanocyte line FM516 (Fig. 1C and D). Likewise, S1P did
not induce IB degradation in FLNA-expressing Sk-mel2 and
Lu1205 cells (Fig. 1E). Remarkably, however, in the course of
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these experiments, we observed that in FLNA-deficient M2 mela-
noma cells, exogenous S1P (100 nM) was able to stimulate IKK
phosphorylation and IB phosphorylation and degradation
(Fig. 1A to C). S1P at this concentration activated ERK1/2 in M2
cells as well as in their FLNA counterpart A7 cells (data not
shown), indicating that the ability of S1P to signal through its cell
surface receptors is not impaired.
S1P induces p65 nuclear translocation and enhances NF-B
DNA binding and reporter activity only in M2melanoma cells.
Following IB degradation, the transcription factor NF-B
composed of p65 and p50 subunits translocates to the nucleus and
regulates gene transcription. As shown in Fig. 2A, TNF induces the
translocation of p65 to the nucleus in A7 cells but not in M2 cells.
Conversely, S1P induced the translocation of p65 to the nucleus
within 30 min only in M2 cells but not in A7 cells. Furthermore,
confocal microscopy also revealed that 100 nM S1P induced sig-
nificant translocation of p65 to the nucleus in M2 cells (Fig. 2B).
S1P also increased the DNA binding activity of NF-B in M2 cells,
as evident in EMSAs (Fig. 2C). In contrast, consistent with data
from a previous report (11), TNF did not increase NF-B DNA
binding activity in M2 cells but readily increased it in A7 cells (Fig.
2D). To further confirm these results, M2 and A7 cells were trans-
fected with an NF-B luciferase reporter and then stimulated with
S1P or TNF. NF-B reporter activity was significantly increased by
S1P or dihydro-S1P, another ligand that binds all of the S1PRs,
only in FLNA-lacking M2 cells, while no effects were observed in
A7 cells (Fig. 2E). Conversely, TNF increased NF-B luciferase
reporter activity only in FLNA-expressing A7 cells but not in M2
cells (Fig. 2E). Altogether, these results suggest that expression of
FLNA prevents NF-B activation induced by extracellular S1P. In
agreement, S1P increased the expression levels of the NF-B-reg-
ulated inflammatory cytokines interleukin-6 (IL-6) and TNF and
the chemokines CCL2 and CCL5 only in M2 but not in A7 cells
(Fig. 3A). Moreover, S1P-stimulated activation of NF-B in M2
cells correlated with S1P suppression of serum withdrawal-in-
duced apoptosis determined by measurement of mono- and oli-
gonucleosomes in lysates of apoptotic cells (Fig. 3B). In contrast,
S1P did not protect A7 cells from apoptosis.
S1PR1 and S1PR2 are involved in activation of NF-B by
S1P. Next, we determined which of the S1PRs are involved in
S1P-induced NF-B activation. As assessed by QPCR, both M2
and A7 cells express S1PR1 to -3, while no message was detected
for S1PR4 or S1PR5 (Fig. 4A). Western blotting also confirmed
the expression of S1PR1 to -3 in both cell lines (Fig. 4B). The
specificity of the S1PR1 and S1PR2 antibodies was confirmed with
HEK293 cells overexpressing these receptors (Fig. 4B). To evalu-
ate which S1PR subtype is involved in NF-B activation, we first
utilized specific S1PR antagonists and examined their effects on
p65 serine 536 phosphorylation that is important for p65 nuclear
import (18). VPC23019 is an antagonist of S1PR1 and S1PR3 at a
high concentration (10 M) but is an S1PR1 antagonist only at a
low concentration (0.3 M) (19). VPC23019 decreased S1P- but
not TNF-induced p65 phosphorylation in M2 and A7 cells, re-
spectively (Fig. 4C). In addition, VPC23019 suppressed S1P-in-
duced IB degradation and p65 phosphorylation at a low con-
centration as effectively as at a high concentration, suggesting the
involvement of S1PR1 (Fig. 4D). In agreement, W146, a S1PR1-
selective competitive antagonist, ablated S1P-stimulated IKK
phosphorylation, although it had only a small effect on ERK1/2
phosphorylation (Fig. 4E). Furthermore, the specific S1PR1 ago-
nist SEW2871 also induced IB degradation (Fig. 4F). Although
the specific S1PR2 antagonist JTE013 did not affect S1P-induced
phosphorylation of p65 (Fig. 4G), surprisingly, CYM-5520, a non-
competitive allosteric agonist of S1PR2, also stimulated the phos-
FIG 1 S1P activates IKK and degradation of IB only in M2 melanoma cells deficient in FLNA. M2 and A7 melanoma cells (A to C), WM35 and FM516
melanoma cells (C and D), and Lu1205 and Sk-mel2 melanoma cells (E) were serum starved overnight and then treated with the vehicle, S1P (100 nM), or TNF
(10 ng/ml) for the indicated times. Equal amounts of cell lysates were separated by SDS-PAGE and immunoblotted with the indicated antibodies. Blots were
stripped and reprobed for tubulin to ensure equal loading and transfer. Numbers indicate relative protein levels determined by densitometry. Blots are
representative of results from at least three independent experiments.
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phorylation of p65 similarly to S1P (Fig. 4G). Therefore, it was of
interest to examine the effects of downregulation of S1PR1 and
S1PR2. siRNA targeted to S1PR1, which decreased its expression
by 77% (Fig. 4H), had no significant effect on S1P-stimulated p65
phosphorylation (Fig. 4I) or nuclear translocation (Fig. 4J). How-
ever, transfection of M2 cells with siRNA targeted to S1PR2, which
reduced its expression by
75% and also somewhat unexpectedly
reduced S1PR1 expression by 70% (Fig. 4H), markedly sup-
pressed S1P-induced p65 phosphorylation (Fig. 4I) as well as its
nuclear translocation (Fig. 4J). These results suggest that in FLNA-
deficient M2 melanoma cells, both S1PR1 and S1PR2 are involved
in the activation of NF-B by S1P.
Activation of NF-B by S1P requires PKC and involves
Bcl10. It was important to examine the intracellular signaling
pathways downstream of S1PR engagement leading to the activa-
tion of NF-B. Because previous studies have shown that PKC is
involved in NF-B activation induced by lysophosphatidic acid
(LPA) (20, 21), another lysophospholipid that signals through
a family of G-protein-coupled receptors (GPCRs) related to
S1PRs (5), we determined whether PKC activity was needed for
S1P-induced NF-B activation. First, pretreatment of M2 cells
with the broad-spectrum PKC inhibitor Go6983 decreased the
phosphorylation of IB and p65 induced by S1P to a similar
extent as the IKK inhibitor Bay 11-7082 (Fig. 5A). Indeed, di-
rect stimulation of PKC with phorbol 12-myristate 13-acetate
(PMA) markedly stimulated IKK phosphorylation and in-
creased IB degradation in a time-dependent manner in M2
cells (Fig. 5B).
FIG 2 S1P promotes p65 translocation, NF-B DNA binding, and reporter activity in FLNA-deficient M2 melanoma cells. (A) M2 and A7 cells were serum
starved overnight and then stimulated with S1P (100 nM) or TNF (10 ng/ml) for 30 min. Nuclear fractions were prepared, and equal amounts of protein were
analyzed by immunoblotting for p65. Lamin A/C was used as a nuclear marker, and tubulin was used as a cytosol marker. (B) M2 cells were serum starved
overnight and then stimulated with S1P for 30 min. Cells were stained with Hoechst dye (blue) or p65 antibody (green) and visualized by confocal microscopy.
Bar, 50m. (C and D) M2 and A7 cells were treated with S1P (100 nM) for the indicated times (C) or with TNF (10 ng/ml) for 30 min (D). NF-B DNA binding
activity in nuclear fractions (5g) was determined by EMSAs. (E) M2 and A7 cells were cotransfected with pNF-B luciferase and -galactosidase plasmids and
then stimulated with S1P (100 nM), dihydro-S1P (dhS1P) (100 nM), or TNF (10 ng/ml) for 18 h. Luciferase activity was normalized to -galactosidase activity
and measured with the Dual-Light reporter gene assay. Data are expressed as fold increases and are means standard errors of the means from three independent
experiments. *, P	 0.01 compared to no treatment.
FIG 3 S1P stimulates expression of NF-B-regulated cytokines and chemokines and protects FLNA-deficient M2 melanoma cells from serum-withdrawal-
induced apoptosis. M2 and A7 cells were serum starved overnight and then treated for 24 h without or with S1P (100 nM) or 10% serum, as indicated. (A) IL-6,
TNF, CCL2, and CCL5 mRNA levels were quantified by QPCR and normalized to GAPDH levels. (B) Apoptosis was analyzed by using the Cell Death Detection
ELISAPlus kit. Data are means  SD. *, P	 0.001, compared to untreated cells. Similar results were obtained in three independent experiments.
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Second, to identify the PKC isoform involved in S1P action, we
utilized phospho-PKC antibodies to evaluate the phosphorylation
status of specific PKC isoforms. Surprisingly, S1P did not enhance
the phosphorylation observed with pan-phospho-PKC antibody,
which detects phosphorylation only at a carboxy-terminal residue
of the PKC , I, II, , ε, and  isoforms (homologous to Ser660
of PKC) (Fig. 6A), nor did it increase the phosphorylation of
PKC at Ser676 (Fig. 6A). However, a significant increase in the
level of phosphorylated PKC at Thr505 in the activation loop and
Ser643 residues that are important for the activation of PKC (22)
FIG4 S1P activates NF-B via S1PR1 and S1PR2. (A and B) M2 and A7 melanoma cells were serum starved overnight. (A) RNA was isolated, and levels of S1PR1
to -3 mRNAs were quantified by QPCR and normalized to GAPDH levels. Data are expressed as relative expression levels and are means standard errors of the
means from three independent experiments. (B) Cell lysates were analyzed by immunoblotting with S1PR-specific antibodies, and tubulin was used as a loading
control. HEK293 cells overexpressing S1PR1 or S1PR2 were used to confirm antibody specificities. MW, molecular weight (in thousands). (C) M2 and A7 cells
were serum starved overnight, pretreated with VPC23019 (VPC) (10M) for 30 min, and then stimulated without or with S1P (100 nM) or TNF (10 ng/ml) for
the indicated times. (D to F) M2 cells were serum starved overnight; pretreated for 30 min with VPC23019 (0.3 or 10M) (D), W146 (10M) (E), or SEW2871
(10 M) (F); and then stimulated without or with S1P (100 nM) for 30 min or the indicated times. (G) M2 cells were serum starved overnight; treated with S1P
(100 nM), CYM-5520 (CYM) (1 M), or both or pretreated with JTE013 (JTE) (10 M) for 30 min; and then stimulated with S1P (100 nM), as indicated. In
panels C to G, cell lysates were analyzed by immunoblotting with the indicated antibodies. Numbers indicate relative protein levels determined by densitometry.
(H to J) M2 cells were transfected with siControl, siS1PR1, or siS1PR2, as indicated. (H) mRNA levels were determined by QPCR and normalized to GAPDH
levels. Data are expressed as relative expression levels compared to those for siControl and are means SD from three independent experiments. *, P	 0.001.
(I and J) Cells were treated without or with S1P (100 nM). In panel I, cell lysates were analyzed by immunoblotting with the indicated antibodies. Numbers
indicate relative protein levels determined by densitometry. (J) Cells were stained with anti-p65 antibody and visualized by confocal microscopy. Blots are
representative of results from three independent experiments.
FIG 5 S1P-induced activation of NF-B involves PKC. (A) M2 cells were serum starved overnight, preincubated with 5M Bay 11-7082 (Bay) or 5M Go6983,
and stimulated with S1P (100 nM) for the indicated times. (B) M2 cells were serum starved overnight and stimulated with PMA (100 nM) for the indicated times.
Cell lysates were analyzed by immunoblotting with the indicated antibodies. Blots were stripped and reprobed with p65 (A) or tubulin (B) to ensure equal loading
and transfer. Blots are representative of results from three (A) and two (B) independent experiments. Numbers indicate relative protein levels determined by
densitometry.
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was clearly evident within 5 min after stimulation with S1P, and
phosphorylation continued for at least 60 min (Fig. 6A).
Finally, to confirm the involvement of PKC in S1P-induced
activation of NF-B, PKC expression in M2 cells was silenced
with a specific siRNA that significantly decreased its expression by
50% 5% (Fig. 6B). Downregulation of PKC reduced S1P-me-
diated phosphorylation of IKK and p65 compared to siControl
(Fig. 6B). Hence, pharmacological and molecular approaches
demonstrate that PKC contributes to S1P-induced activation of
NF-B in melanoma cells lacking FLNA.
As there is increasing evidence that the adaptor protein Bcl10
(B-cell lymphoma 10) is a key signaling component in PKC-me-
diated IKK activation induced by the ligation of LPA receptors
(21, 23), the requirement for Bcl10 was then examined. Similar to
the effect of siRNA for PKC (siPKC), siRNA that diminished
Bcl10 expression by 45% 9% reduced S1P-mediated phosphor-
ylation of IKK but not phosphorylation of STAT3 (Tyr705) (Fig.
6C), supporting the notion that Bcl10 is involved in the signaling
pathway leading to IKK phosphorylation and subsequently to
NF-B activation.
Akt activation is crucial for S1P-induced NF-B activation.
Our data suggest that the activation of NF-B by exogenous S1P
inversely correlates with the presence of FLNA. To convincingly
demonstrate that FLNA negatively regulates S1P-mediated NF-B
activation, FLNA-expressing A7 cells were transfected with siRNA
targeting FLNA. Western blot analysis shows that residual FLNA
expression after silencing was 19%  0.9% (n  6). Decreasing
FLNA expression restored the ability of S1P to induce IB deg-
radation (Fig. 7A). It was then important to determine how FLNA
negatively regulates S1P-mediated signaling leading to NF-B ac-
tivation. It was recently shown that FLNA can function as a nega-
tive regulator of the PI3K/Akt signaling of some GPCRs contain-
ing both a FLNA binding motif and the PI3K regulatory p85
subunit binding YXXM motif in close proximity in an intracellu-
lar loop sequence (24). As a consequence, upon ligand treatment,
the PI3K regulatory p85 subunit dissociates from the GPCR,
which now associates with FLNA. This switch causes an inhibition
of PI3K/Akt signaling (24). Interestingly, S1PR1 is the sole S1P
receptor that contains both of these motifs (24) (Fig. 7B). Thus, it
was important to examine the effect of FLNA expression on Akt
activation induced by S1P. Although, as expected, S1P stimulated
the phosphorylation of ERK1/2 in both M2 and A7 cells, it did not
have any effect on the high basal phospho-Akt levels in M2 cells.
However, remarkably, S1P diminished Akt phosphorylation in
FLNA-expressing A7 cells in a time-dependent manner (Fig. 7C),
whereas after downregulation of FLNA, S1P no longer inhibited
the phosphorylation of Akt (Fig. 7A). These results suggest that in
the presence of FLNA, S1P negatively regulates the PI3K/Akt path-
way, while the absence of FLNA enables high basal PI3K/Akt ac-
tivation, which in turn is critical for IKK phosphorylation and
NF-B activation. To substantiate the role of PI3K/Akt in S1P-
induced NF-B activation, M2 cells were treated with the PI3K
inhibitors wortmannin and LY294002 (Fig. 8A and B). Wortman-
nin treatment reduced IKK phosphorylation, and both wortman-
nin and LY294002 delayed S1P-induced IB degradation (Fig.
8A and B). Similarly, IB degradation induced by PMA was also
partially suppressed by wortmannin treatment, whereas PMA-in-
duced ERK1/2 phosphorylation was unaltered (Fig. 8C). More-
over, MK-2206, a potent allosteric Akt inhibitor, also significantly
reduced IKK phosphorylation and degradation of IB as well as
phosphorylation of p65, concomitantly with the inhibition of Akt
phosphorylation (Fig. 8D). We also investigated the relationship
between PKC and Akt in S1P-induced NF-B activation. While
specific pharmacological inhibition of PKC by rottlerin treat-
ment (25) slightly delayed IB degradation, it had no discernible
effect on the phosphorylation of Akt (Fig. 8E). Moreover, in con-
trast to the inability of S1P to stimulate NF-B in FLNA-express-
ing A7 cells, direct activation of PKC with PMA induced the deg-
radation of IB in these cells (Fig. 8F).
To further support the role of activated Akt in S1P-induced
NF-B activation, we generated A7 cells expressing constitutively
active, myristoylated Akt (26). Remarkably, in these cells, S1P was
then able to induce IB degradation even in the presence of
FLNA (Fig. 9A), in sharp contrast to control transfected cells.
Interestingly, LPA, another bioactive lysolipid that is a ligand for a
closely related family of GPCRs (5), unlike S1P, was able to induce
IB degradation even in A7 cells (Fig. 9B).
Next, we wondered whether S1P also reduced Akt activation
and was unable to activate NF-B in other FLNA-expressing cells.
Similarly to A7 cells, in Lu1205 melanoma cells that also express
FIG 6 PKC and Bcl10 are involved in S1P-mediated NF-B activation. (A) M2 cells were serum starved overnight and stimulated with S1P (100 nM) for the
indicated times. (B and C) M2 cells were transfected with control siRNA or siRNA directed against PKC (B) or Bcl10 (C). After 48 h, cells were serum starved
overnight and stimulated with S1P (100 nM). Cell lysate proteins were analyzed by immunoblotting with the indicated antibodies. Tubulin (A and C) or p65 (B)
was used to ensure equal loading and transfer. Blots are representative of results from two independent experiments. Numbers indicate relative protein levels
determined by densitometry.
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FLNA (Fig. 1C), S1P, in contrast to TNF, was unable to induce
IBdegradation (Fig. 9C). Importantly, as with A7 cells, S1P also
greatly reduced the phosphorylation of Akt in Lu1205 cells,
whereas treatment with TNF had no significant effect (Fig. 9C).
Because Lu1205 cells have a BRAFV600E mutation resulting in the
activation of ERK1/2, levels of phosphorylated ERK1/2 (p-
ERK1/2) are high and do not change with S1P treatment. More-
over, in SH-SY5Y neuroblastoma cells that also express FLNA,
S1P did not induce IB degradation, while it reduced the levels
of phosphorylated Akt (Fig. 9D). Altogether, these results indicate
that in the presence of FLNA, S1P reduces the phosphorylation of
Akt and can no longer stimulate NF-B.
DISCUSSION
We previously showed that intracellular S1P generated by SphK1
functions as a cofactor for TRAF2 and is required to link TNF
signaling to NF-B activation in melanoma cells (13). Interest-
ingly, activation of NF-B by TNF occurs only in the presence of
FLNA (11), which interacts with many signaling proteins, includ-
ing TRAF2 (10, 11). As SphK1 also physically interacts with FLNA
(9), FLNA may act as a scaffold to allow localized production of
S1P, which in turn binds and activates TRAF2, leading to NF-B
signaling. Recent studies have shown that TRAF-interacting pro-
tein (TRIP), a known cellular binding partner of TRAF2 (27),
inhibits TNF-induced NF-B activation by inhibiting the binding
of S1P to TRAF2 and thus suppressing its E3 ubiquitin ligase ac-
tivity (28).
We have now demonstrated that FLNA negatively regulates the
activation of NF-B induced by extracellular S1P in melanoma
cells. Thus, S1P activates NF-B only in M2 cells that are devoid of
FLNA. In contrast, in their counterpart A7 melanoma cells that
express FLNA, S1P does not activate NF-B unless the expression
of FLNA is downregulated. Several previous reports suggested that
S1P can activate NF-B via S1PRs (14, 15, 29–34). Although in
some studies, the S1PR involved was not identified and the concen-
tration of S1P used was too high to substantiate the involvement of
S1PR-mediated events (35), others have clearly implicated S1PR1 to
-3 in different cell types. For example, S1P-induced activation of
NF-B in human umbilical vein endothelial cells (HUVECs) was
abrogated by pertussis toxin, suggesting the involvement of inhib-
itory G protein (Gi)-dependent mechanisms (32). However, S1P
induced the activation of NF-B in HEK293 cells overexpressing
S1PR2 or S1PR3 but not S1PR1 (33). Subsequently, specific anti-
sense oligonucleotides were used to show that the activation of
NF-B in HUVECs requires mainly S1PR3 and, to a much lesser
extent, S1PR1 (15). Moreover, pharmacological and siRNA exper-
iments substantiated the involvement of S1PR1 and S1PR3 in
NF-B activation in cooperation with lipopolysaccharide (LPS) to
induce inflammatory molecules and leukocyte adhesion in endo-
thelial cells (29). Surprisingly, S1PRs have been linked not only to
stimulatory pathways leading to the activation of NF-B but also
to inhibitory pathways in HUVECs. Whereas the stimulatory
pathway was mediated mainly by S1PR3 coupled to G12/13 lead-
ing to NF-B activation, the inhibitory pathway was mediated by
S1PR1 coupled to Gi and PI3K/Akt leading to the activation of
endothelial nitric oxide synthase (eNOS) and the production of
NO, which suppressed TNF-mediated NF-B activation (31).
However, in HeLa cells, S1PR2, but not S1PR1 or S1PR3, was
responsible for the activation of NF-B induced by extracellular
S1P (14). In addition, S1PR2 induced endothelial inflammation
by the activation of the Rho-ROCK (Rho-associated protein ki-
nase) pathway leading to NF-B activation (34). Using M2 mela-
FIG7 S1P decreases Akt phosphorylation in FLNA-expressing cells. (A) A7 cells were transfected with control siRNA or siFLNA. After overnight starvation, cells
were treated with S1P (100 nM) for the indicated times. (B) Sequence alignment of the S1PRs showing that only S1PR1 contains both the FLNA binding motif
and the YXXM sequence in close proximity in intracellular loop 2. (C) A7 and M2 cells were serum starved overnight and stimulated with S1P (100 nM) or TNF
(10 ng/ml), as indicated. Cell lysates were analyzed by immunoblotting with the indicated antibodies. Tubulin, actin, and total Akt were used as indicated to
ensure equal loading and transfer. Histograms show densitometric quantification of IB and p-Akt for A7 and M2 cells. #, P	 0.05; *, P	 0.01; **, P	 0.001
(compared to untreated cells [None]). Blots are representative of results from at least three independent experiments.
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noma cells, we have now provided evidence showing that both
S1PR1 and S1PR2 are involved in the activation of NF-B by S1P.
This is based on the use of S1PR1- and S1PR2-specific antagonists
and agonists as well as the downregulation of these receptors. Of
note, siRNA targeted to S1PR2 unexpectedly reduced the expres-
sion levels of both S1PR2 and S1PR1 and markedly suppressed the
activation of NF-B by exogenous S1P. Activation of NF-B by
S1P in FLNA-deficient melanoma cells might contribute to the
increased expression of proinflammatory cytokines and chemo-
kines, which have been associated with tumor progression (36),
and increase the survival of cancer cells, which directly enhances
tumor growth.
Although many PKC isoforms, including atypical PKCs (37),
have been implicated in NF-B activation, we noted that S1P in-
duced time-dependent phosphorylation of PKC without affect-
ing the activation of other PKCs. Moreover, downregulation of
PKC greatly reduced S1P-mediated IKK phosphorylation and
NF-B activation, supporting a role for this PKC isoform in
NF-B activation. Similarly, in response to LPA, PKC was re-
quired for NF-B activation and IL-8 secretion in bronchial epi-
FIG 8 Role of Akt activation in S1P-induced NF-B activation. (A to E) M2 cells were starved overnight; preincubated for 30 min with 100 nM wortmannin (A
and C), 50M LY294002 (B),100 nM Mk2206 (D), or 1M rottlerin (E); and then stimulated with S1P (100 nM) or PMA (100 nM) for the indicated times. (F)
A7 cells were starved overnight and treated with PMA (100 nM), as indicated. Cell lysate proteins were analyzed by immunoblotting with the indicated antibodies.
Tubulin or Akt was used to ensure equal loading and transfer. Numbers indicate relative protein levels determined by densitometry. Blots are representative of
results from two or three independent experiments.
FIG 9 Role of Akt in S1P-induced IB degradation in FLNA-expressing cells. (A) A7 cells expressing GFP or myristoylated Akt (myrAkt) were starved
overnight and stimulated with S1P (100 nM) for the indicated times. Numbers indicate relative protein levels determined by densitometry, normalized to the
levels in the respective untreated cells. (B) A7 cells were serum starved overnight and treated with LPA (1M). (C and D) Lu1205 cells (C) and SH-SY5Y cells (D)
were serum starved overnight and stimulated with S1P (100 nM) or TNF (10 ng/ml), as indicated. In panels A to D, cell lysates were analyzed by immunoblotting
with the indicated antibodies. Where indicated, tubulin and total Akt were used to ensure equal loading and transfer. Numbers indicate relative protein levels
determined by densitometry.
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thelial cells (20). In this regard, PMA-induced NF-B activation
was shown to involve PKC and PKCε (38). Moreover, PKC
orchestrates p65 activation in response to TNF (39, 40).
It has been suggested that in response to LPA, PKC-dependent
phosphorylation of the scaffold protein CARD (caspase recruit-
ment domain) and membrane-associated guanylate kinase-like
domain-containing protein 3 (CARMA3) (41) induces a confor-
mational change and permits its interaction with Bcl10 and
MALT1 (mucosa-associated lymphoid tissue lymphoma translo-
cation protein 1), and oligomerized MALT1 interacts with the
ubiquitin ligase TRAF6. The subsequent ubiquitination of the IKK
complex then results in optimal IKK-mediated NF-B activation
(23, 42). Likewise, we found that Bcl10 is involved in S1P-induced
IKK phosphorylation and NF-B activation, and its downregula-
tion greatly reduced this pathway. Hence, it is likely that a similar
signaling pathway involving PKC and the CARMA3-Bcl10-
MALT1 complex that activates IKK in LPA signaling also exists
downstream of S1P signaling.
Activation of NF-B by the S1P/S1PR axis was not observed in
several types of FLNA-expressing melanoma cells. This raised an
intriguing question: how does FLNA negatively regulate this path-
way? Our results support the proposal that in FLNA-expressing
cells, for GPCRs that contain a FLNA binding motif and the PI3K
regulatory p85 subunit binding motif in close proximity, upon
ligand binding (such as S1P), the cognate receptor switches its
binding preference from p85 to FLNA (24). This switch results in
the dissociation of p85 and inhibition of the PI3K/Akt pathway.
Although FLNA expression does not regulate the activation of
NF-B induced by LPA, it was previously shown that FLNA inter-
acts with other GPCRs, such as the mu opioid receptor and the
somatostatin sst2 receptor, to negatively regulate the PI3K-Akt
pathway (24). However, although FLNA expression was originally
implicated in cell migration, invasion, and metastasis, recent re-
ports suggest that under certain conditions, it prevents tumor for-
mation or progression (10). In this regard, it is tempting to spec-
ulate that inhibition of the PI3K/Akt pathway by FLNA might
contribute to these effects.
Several lines of evidence support the notion that activation of
Akt is necessary for the full activation of the NF-B pathway by
S1P. First, inhibitors of PI3K or Akt greatly reduced S1P-induced
IKK activation. Second, S1P reduced Akt phosphorylation only in
FLNA-expressing cells. Third, downregulation of FLNA restored
the ability of S1P to induce IB degradation and prevented it
from decreasing the phosphorylation of Akt. Finally, overexpres-
sion of myristoylated, constitutively active Akt allowed S1P to
induce IB degradation in A7 FLNA-expressing cells. This is
consistent with data from previous studies showing that Akt-me-
diated regulation of NF-B is dependent on its phosphorylation of
IKK, a prerequisite for the phosphorylation of p65 by IKK and
- (43). Intriguingly, although both PKC and PI3K/Akt are im-
portant for S1P-induced NF-B activation in FLNA-deficient M2
cells, our data suggest that FLNA expression suppresses S1P-me-
diated NF-B activation only by modulation of the PI3K/Akt
pathway. Taken together, our results support a negative role for
FLNA in S1P-mediated NF-B activation in melanoma cells by
inhibition of Akt.
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